Adagio Medical Q2 FY26 net loss widens to $6.7 million; revenue posts no revenue

• Adagio Medical posted a Q2 net loss of $6.7 million, or $(0.30) a share, widening from a $3.9 million loss year earlier.
• Research and development expense rose to $2.5 million from $2 million, on higher product development and operational costs.
• Selling, general and administrative costs edged up to $2.5 million from $2.4 million, on higher stock-based compensation.
• Cash and cash equivalents fell to $7.7 million at June 30 from $17.1 million at Dec. 31.
• Submitted an FDA PMA for the vCLAS Ventricular Ablation System; reported FULCRUM-VT results showing 2.4% major adverse events and 84% freedom from ICD shock at six months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811176104) on August 11, 2026, and is solely responsible for the information contained therein.